133 related articles for article (PubMed ID: 27775362)
1. Effect of Mutation on an Aggregation-Prone Segment of p53: From Monomer to Dimer to Multimer.
Das A; Makarov DE
J Phys Chem B; 2016 Nov; 120(45):11665-11673. PubMed ID: 27775362
[TBL] [Abstract][Full Text] [Related]
2. Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant.
Lei J; Qi R; Wei G; Nussinov R; Ma B
Phys Chem Chem Phys; 2016 Mar; 18(11):8098-107. PubMed ID: 26923710
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation.
Lei J; Cai M; Shen Y; Lin D; Deng X
Phys Chem Chem Phys; 2021 Oct; 23(40):23032-23041. PubMed ID: 34612239
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
5. Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53.
Ghosh S; Ghosh D; Ranganathan S; Anoop A; P SK; Jha NN; Padinhateeri R; Maji SK
Biochemistry; 2014 Sep; 53(38):5995-6010. PubMed ID: 25181279
[TBL] [Abstract][Full Text] [Related]
6. Biophysical characterization of p53 core domain aggregates.
Lima I; Navalkar A; Maji SK; Silva JL; de Oliveira GAP; Cino EA
Biochem J; 2020 Jan; 477(1):111-120. PubMed ID: 31841126
[TBL] [Abstract][Full Text] [Related]
7. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
8. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.
Herzog G; Shmueli MD; Levy L; Engel L; Gazit E; Klärner FG; Schrader T; Bitan G; Segal D
Biochemistry; 2015 Jun; 54(24):3729-38. PubMed ID: 26030124
[TBL] [Abstract][Full Text] [Related]
9. Characterization of full-length p53 aggregates and their kinetics of formation.
Julian L; Sang JC; Wu Y; Meisl G; Brelstaff JH; Miller A; Cheetham MR; Vendruscolo M; Knowles TPJ; Ruggeri FS; Bryant C; Ros S; Brindle KM; Klenerman D
Biophys J; 2022 Nov; 121(22):4280-4298. PubMed ID: 36230002
[TBL] [Abstract][Full Text] [Related]
10. Tumorigenic p53 mutants undergo common structural disruptions including conversion to α-sheet structure.
Bromley D; Daggett V
Protein Sci; 2020 Sep; 29(9):1983-1999. PubMed ID: 32715544
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
12. Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics.
Ferretti GDDS; da Costa DCF; L Silva J; Pereira Rangel L
Methods Mol Biol; 2019; 1873():265-277. PubMed ID: 30341616
[TBL] [Abstract][Full Text] [Related]
13. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
14. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations.
Li L; Li X; Tang Y; Lao Z; Lei J; Wei G
Phys Chem Chem Phys; 2020 May; 22(17):9225-9232. PubMed ID: 32307496
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of p53 Mutant Peptide Aggregation In Vitro by Cationic Osmolyte Acetylcholine Chloride.
Chen Z; Kanapathipillai M
Protein Pept Lett; 2017; 24(4):353-357. PubMed ID: 28117010
[TBL] [Abstract][Full Text] [Related]
16. Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer.
Higashimoto Y; Asanomi Y; Takakusagi S; Lewis MS; Uosaki K; Durell SR; Anderson CW; Appella E; Sakaguchi K
Biochemistry; 2006 Feb; 45(6):1608-19. PubMed ID: 16460008
[TBL] [Abstract][Full Text] [Related]
17. Multisite aggregation of p53 and implications for drug rescue.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2634-E2643. PubMed ID: 28292898
[TBL] [Abstract][Full Text] [Related]
18. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
19. Impact of Cu(II) Binding on Structures and Dynamics of Aβ
Huy PD; Vuong QV; La Penna G; Faller P; Li MS
ACS Chem Neurosci; 2016 Oct; 7(10):1348-1363. PubMed ID: 27454036
[TBL] [Abstract][Full Text] [Related]
20. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.
Palanikumar L; Karpauskaite L; Al-Sayegh M; Chehade I; Alam M; Hassan S; Maity D; Ali L; Kalmouni M; Hunashal Y; Ahmed J; Houhou T; Karapetyan S; Falls Z; Samudrala R; Pasricha R; Esposito G; Afzal AJ; Hamilton AD; Kumar S; Magzoub M
Nat Commun; 2021 Jun; 12(1):3962. PubMed ID: 34172723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]